What Is the Difference Between IPF and Other ILDs?

Patients and even some medical resources often use the terms “ILD” and “IPF” interchangeably, but they do not mean the same thing. Interstitial lung disease (ILD) is a broad umbrella term for a group of more than 200 distinct conditions that cause inflammation, scarring (fibrosis), or a mix of both in the tissues of the lungs ^{[1] [2]}. Idiopathic pulmonary fibrosis (IPF) is one specific type of ILD. The main difference is that IPF is a primarily scarring (fibrosis-predominant) disease where no underlying cause can be identified, whereas many other ILDs are linked to specific autoimmune conditions or environmental exposures ^{[3] [1]}. Understanding exactly which type of ILD you have is critical because the medication strategy used to treat IPF is fundamentally different from the strategies used for other types of ILD ^[4].

The ILD Umbrella vs. IPF

If your doctor tells you that you have an interstitial lung disease, they are identifying the general category of your problem. Within this large family of diseases, conditions generally fall into a few different buckets:

• Autoimmune-related ILDs: Conditions where the body’s immune system attacks the lungs. This is often seen in connective tissue diseases like systemic sclerosis or rheumatoid arthritis ^{[4] [5]}.
• Exposure-related ILDs: Conditions triggered by an immune reaction to inhaling specific substances (antigens) over time. For example, hypersensitivity pneumonitis is an immune response to organic particles like bird feathers, down bedding, mold, or agricultural dust ^{[5] [6]}.
• Medication-induced ILDs: Lung scarring or inflammation caused as a side effect of certain drugs or therapies ^[7].
• Idiopathic Interstitial Pneumonias: ILDs where no specific trigger, exposure, or autoimmune cause can be found after a thorough evaluation.

IPF belongs to this last bucket. The word “idiopathic” means “of unknown cause.” To diagnose IPF, your medical team looks for a specific pattern of lung scarring—often called Usual Interstitial Pneumonia (UIP)—and must thoroughly rule out other potential causes like autoimmune diseases or exposures ^{[3] [1]}.

Note on “UIP”: UIP is just a radiologic or microscopic pattern of scarring; despite the word “pneumonia,” it is not an infection. Importantly, a UIP pattern on a CT scan can also occur in hypersensitivity pneumonitis or connective-tissue diseases, which is why a scan alone cannot automatically confirm a diagnosis of IPF ^{[5] [8]}.

Because IPF is a chronic condition, lung function declines over time. However, the rate of progression varies greatly from person to person—some remain stable for long periods, while others decline more rapidly.

Why the Distinction Changes Your Treatment

The difference between IPF and other ILDs completely changes the primary medication strategy.

For non-IPF ILDs that are linked to environmental exposures or autoimmune conditions, the disease may be driven heavily by active immune inflammation. The foundational treatment often involves removing the offending exposure (like a moldy environment or bird proteins) or using immunosuppressive medications to calm down the overactive immune system ^{[6] [9]}.

However, IPF is a fibrosis-predominant disease where no external cause has been identified ^[1]. Because of this, using immunosuppressant medications is not the standard therapy for IPF and is generally reserved for specific non-IPF inflammatory cases ^{[9] [1]}. Instead, the standard treatment for IPF relies on antifibrotic medications (such as nintedanib or pirfenidone) ^[10]. These drugs do not suppress the immune system; rather, they work to slow down the biological pathways that cause scar tissue to build up. It is important to know that antifibrotics are designed to slow the loss of lung function, but they cannot cure the disease or reverse existing scars.

Regardless of whether you have IPF or another ILD, supportive care is vital. This includes smoking cessation (avoiding inhaled hazards is always important), pulmonary rehabilitation, vaccinations, oxygen therapy if needed, and managing comorbidities like acid reflux ^[6].

When the Lines Blur: Progressive Pulmonary Fibrosis (PPF)

While the treatment paths start out differently, they can sometimes overlap. Some non-IPF conditions—like hypersensitivity pneumonitis or autoimmune ILDs—can eventually develop a progressive fibrotic phenotype ^{[1] [2]}. This means that the lung scarring continues to worsen (measured by worsening symptoms, lung function tests, or CT scans) even when the underlying inflammation is being treated ^[4].

If a non-IPF ILD progresses in this way despite appropriate management, a patient may be considered for antifibrotic therapy ^{[11] [12]}. For example, nintedanib has been shown to reduce lung-function decline in progressive fibrosing ILDs and is approved for this use in many regions, whereas pirfenidone’s use for non-IPF conditions is less universally established ^{[13] [14]}.

Because diagnosing and treating these complex pathways is difficult, it is highly recommended that cases be reviewed by a multidisciplinary ILD team (including pulmonologists, radiologists, and pathologists) to ensure accurate diagnosis and the most effective individualized treatment plan ^[15].

Quick Comparison